{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:23:29Z","timestamp":1761675809920},"reference-count":75,"publisher":"Baishideng Publishing Group Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJO"],"published-print":{"date-parts":[[2010]]},"DOI":"10.5312\/wjo.v1.i1.3","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T09:07:23Z","timestamp":1290071243000},"page":"3","source":"Crossref","is-referenced-by-count":21,"title":["Bone fragility in type 2 diabetes mellitus"],"prefix":"10.5312","volume":"1","author":[{"given":"Toru","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.","DOI":"10.1152\/physrev.1989.69.3.990"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Price PA. Gla-containing proteins of bone. Connect Tissue Res 1989;21:51-57; discussion 57-60.","DOI":"10.3109\/03008208909049995"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY. Endocrine regulation of energy metabolism by the skeleton. Cell 2007;130:456-469.","DOI":"10.1016\/j.cell.2007.05.047"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008;105:5266-5270.","DOI":"10.1073\/pnas.0711119105"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:45-49.","DOI":"10.1210\/jc.2008-1455"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellström D. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 2009;24:785-791.","DOI":"10.1359\/jbmr.081234"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fernández-Real JM, Izquierdo M, Ortega F, Gorostiaga E, Gómez-Ambrosi J, Moreno-Navarrete JM, Frühbeck G, Martínez C, Idoate F, Salvador J. The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab 2009;94:237-245.","DOI":"10.1210\/jc.2008-0270"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B. Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 2009;94:827-832.","DOI":"10.1210\/jc.2008-1422"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 2010;Epub ahead of print.","DOI":"10.1007\/s00198-010-1184-7"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278-1282.","DOI":"10.1126\/science.1136370"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Smith U. TCF7L2 and type 2 diabetes--we WNT to know. Diabetologia 2007;50:5-7.","DOI":"10.1007\/s00125-006-0521-z"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.","DOI":"10.1038\/ng1732"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Owen KR, McCarthy MI. Genetics of type 2 diabetes. Curr Opin Genet Dev 2007;17:239-244.","DOI":"10.1016\/j.gde.2007.04.003"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-1345.","DOI":"10.1126\/science.1142382"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Manolagas SC, Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007;21:2605-2614.","DOI":"10.1210\/me.2007-0259"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hoogeboom D, Burgering BM. Should I stay or should I go: beta-catenin decides under stress. Biochim Biophys Acta 2009;1796:63-74.","DOI":"10.1016\/j.bbcan.2009.02.002"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"DeCarolis NA, Wharton KA Jr, Eisch AJ. Which way does the Wnt blow? Exploring the duality of canonical Wnt signaling on cellular aging. Bioessays 2008;30:102-106.","DOI":"10.1002\/bies.20709"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008;51:1771-1780.","DOI":"10.1007\/s00125-008-1084-y"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010;31:266-300.","DOI":"10.1210\/er.2009-0024"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int 2007;18:427-444.","DOI":"10.1007\/s00198-006-0253-4"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505.","DOI":"10.1093\/aje\/kwm106"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Bone mineral density is not sensitive enough to assess the risk of vertebral fractures in type 2 diabetic women. Calcif Tissue Int 2007;80:353-358.","DOI":"10.1007\/s00223-007-9003-7"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009;24:702-709.","DOI":"10.1359\/jbmr.081207"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.","DOI":"10.1146\/annurev.med.46.1.223"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.","DOI":"10.1056\/NEJM198805193182007"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.","DOI":"10.1161\/CIRCULATIONAHA.106.621854"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van der Ham F, DeGroot J, Bank RA, Keaveny TM. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 2005;37:825-832.","DOI":"10.1016\/j.bone.2005.07.019"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002;31:1-7.","DOI":"10.1016\/S8756-3282(01)00697-4"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T. Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997;12:439-446.","DOI":"10.1359\/jbmr.1997.12.3.439"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001;38:S161-S164.","DOI":"10.1053\/ajkd.2001.27428"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996;11:931-937.","DOI":"10.1002\/jbmr.5650110709"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166-172.","DOI":"10.1196\/annals.1433.044"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 2007;39:871-875.","DOI":"10.1055\/s-2007-991157"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomi S. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-270.","DOI":"10.1681\/ASN.V82260"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006;340:1091-1097.","DOI":"10.1016\/j.bbrc.2005.12.107"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 2006;39:1073-1079.","DOI":"10.1016\/j.bone.2006.05.013"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010;21:195-214.","DOI":"10.1007\/s00198-009-1066-z"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Garnero P, Borel O, Gineyts E, Duboeuf F, Solberg H, Bouxsein ML, Christiansen C, Delmas PD. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 2006;38:300-309.","DOI":"10.1016\/j.bone.2005.09.014"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Vashishth D. The role of the collagen matrix in skeletal fragility. Curr Osteoporos Rep 2007;5:62-66.","DOI":"10.1007\/s11914-007-0004-2"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Banse X, Sims TJ, Bailey AJ. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 2002;17:1621-1628.","DOI":"10.1359\/jbmr.2002.17.9.1621"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN\/Kob rats. Osteoporos Int 2006;17:1514-1523.","DOI":"10.1007\/s00198-006-0155-5"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;41:153-159.","DOI":"10.2337\/diab.41.2.153"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Monnier VM, Sell DR, Nagaraj RH, Miyata S, Grandhee S, Odetti P, Ibrahim SA. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992;41 Suppl 2:36-41.","DOI":"10.2337\/diab.41.2.S36"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991;266:11649-11653.","DOI":"10.1016\/S0021-9258(18)99006-X"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Saito M, Fujii K, Soshi S, Tanaka T. Reductions in degree of mineralization and enzymatic collagen cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 2006;17:986-995.","DOI":"10.1007\/s00198-006-0087-0"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006;79:160-168.","DOI":"10.1007\/s00223-006-0035-1"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, Federici A. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005;1043:710-717.","DOI":"10.1196\/annals.1333.082"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008;93:1013-1019.","DOI":"10.1210\/jc.2007-1270"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009;94:2380-2386.","DOI":"10.1210\/jc.2008-2498"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740-31749.","DOI":"10.1074\/jbc.274.44.31740"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268.","DOI":"10.1172\/JCI11771"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003;370:1097-1109.","DOI":"10.1042\/bj20021371"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998;4:1025-1031.","DOI":"10.1038\/2012"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 2009;32:2263-2268.","DOI":"10.2337\/dc09-0901"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Canalis E. The hormonal and local regulation of bone formation. Endocr Rev 1983;4:62-77.","DOI":"10.1210\/edrv-4-1-62"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Mohan S, Baylink DJ. Bone growth factors. Clin Orthop Relat Res 1991;30-48.","DOI":"10.1097\/00003086-199102000-00004"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ueland T. Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res 2004;14:404-417.","DOI":"10.1016\/j.ghir.2004.06.002"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"McCarthy TL, Centrella M, Canalis E. Insulin-like growth factor (IGF) and bone. Connect Tissue Res 1989;20:277-282.","DOI":"10.3109\/03008208909023897"},{"key":"ref59","unstructured":"Mohan S. Insulin-like growth factor binding proteins in bone cell regulation. Growth Regul 1993;3:67-70."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002;277:44005-44012.","DOI":"10.1074\/jbc.M208265200"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Johansson AG, Lindh E, Ljunghall S. Insulin-like growth factor I stimulates bone turnover in osteoporosis. Lancet 1992;339:1619.","DOI":"10.1016\/0140-6736(92)91889-G"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Schwander JC, Hauri C, Zapf J, Froesch ER. Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status. Endocrinology 1983;113:297-305.","DOI":"10.1210\/endo-113-1-297"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Spencer EM, Liu CC, Si EC, Howard GA. In vivo actions of insulin-like growth factor-I (IGF-I) on bone formation and resorption in rats. Bone 1991;12:21-26.","DOI":"10.1016\/8756-3282(91)90050-S"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002;110:771-781.","DOI":"10.1172\/JCI0215463"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997;12:1272-1279.","DOI":"10.1359\/jbmr.1997.12.8.1272"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Yamaguchi T, Kanatani M, Yamauchi M, Kaji H, Sugishita T, Baylink DJ, Mohan S, Chihara K, Sugimoto T. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int 2006;78:18-24.","DOI":"10.1007\/s00223-005-0163-z"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Thrailkill KM. Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility. Diabetes Technol Ther 2002;2:69-80.","DOI":"10.1089\/152091599316775"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Ahmad T, Ugarph-Morawski A, Lewitt MS, Li J, Sääf M, Brismar K. Diabetic osteopathy and the IGF system in the Goto-Kakizaki rat. Growth Horm IGF Res 2008;18:404-411.","DOI":"10.1016\/j.ghir.2008.02.003"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S. Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 1998;22:17-23.","DOI":"10.1016\/S8756-3282(97)00220-2"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"McCarthy AD, Etcheverry SB, Cortizo AM. Effect of advanced glycation endproducts on the secretion of insulin-like growth factor-I and its binding proteins: role in osteoblast development. Acta Diabetol 2001;38:113-122.","DOI":"10.1007\/s005920170007"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 2007;18:1675-1681.","DOI":"10.1007\/s00198-007-0430-0"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1999;14:821-828.","DOI":"10.1359\/jbmr.1999.14.5.821"},{"key":"ref73","unstructured":"Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443."},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N. Assessment of fracture risk. Osteoporos Int 2005;16:581-589.","DOI":"10.1007\/s00198-004-1780-5"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009;44:734-743.","DOI":"10.1016\/j.bone.2009.01.373"}],"container-title":["World Journal of Orthopedics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T18:45:31Z","timestamp":1636829131000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/2218-5836\/full\/v1\/i1\/3.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.5312\/wjo.v1.i1.3","relation":{},"ISSN":["2218-5836"],"issn-type":[{"value":"2218-5836","type":"print"}],"subject":[],"published":{"date-parts":[[2010]]}}}